Editors' (re)View

Welcome to Editors' (re)View, our editors’ weekly takes on things going on in the pharma world that deserve some extra consideration.

Articles

Editors' (re)View: McKinsey under fire for opioid crisis; Nexus gives up its generic plant

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 21

Editors' (re)View: A new obesity startup; Schizophrenia treatment happenings

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 15.

Editors' (re)View: Advancing mental health treatment; CMS proposes financial incentives for gene therapy access

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 8

Editors' (re)View: ALS and drug approval criteria; Verve trial paused again

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 1

Editors' (re)View: J&J can contest talc scientific evidence; SCOTUS mifepristone hearing met with skepticism

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 25

Editors' (re)View: J&J cast-off anti-hypertensive wins approval; Orchard prices MLD therapy at $4.25M

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 18

Editors' (re)View: FDA shares early AD industry guidance; WuXi-BIO breakup

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 11

Editors' (re)View: Perrigo launches OTC birth control; Lilly takes aim at celebs

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 4

Editors' (re)View: Probing pharma-sponsored testing; FDA approves Alvotech-Teva Humira biosim 

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of February 24

Editors' (re)View: Landmark approval for solid tumors; Relief for food allergy sufferers 

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of February 19

Editors' (re)View: Humira's patent blip; Hope for pancreatic cancer

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of February 12

Editors' (re)View: Lilly weighs in on Novo deal; J&J drug brings immune disease hope

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of February 5

Editors' (re)View: CMS commits to improving CGT access; The Aduhelm exit

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of January 28

Editors' (re)View: Lilly's hearing loss win; Sandoz is open for business

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of Jan 22

Editors' (re)View: FTC wins another battle; Weight loss side effects

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of January 8